Latest From OncoTherics Ltd.
This Month's Profile Group, BioHub At Alderley Park, features profiles of Absynth Biologics, Blueberry Therapeutics, Molplex Pharmaceuticals, and OncoTherics. Plus these Start-Ups Across Health Care: Centerline Biomedical, Laurimed, and Portal Instruments.
Cancers, even those that initially respond to treatment, can become resistant to chemotherapy and radiotherapy; one of the causes behind this is the hypoxia found in some tumors. OncoTherics Ltd. is tackling this by developing non-toxic prodrugs that are activated to potent anticancer drugs in hypoxic conditions, selectively targeting the hard-to-treat cancer cells but sparing healthy tissue.
Once an R&D site for AstraZeneca, the BioHub at Alderley Park is now home to a number of emerging biotechs. Profiles of Absynth Biologics, Blueberry Therapeutics, Molplex, and OncoTherics.
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- OncoTherics Ltd.
- Senior Management
Paul Smith, PhD, Scientific Dir.
Mike Leyland, Finance Dir.
- Contact Info
Phone: 1509 558 163
BioHub at Alderley Park, Mereside
Cheshire, SK10 4TG
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.